Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Watching closely again!

$Outlook Therapeutics(OTLK.US)$ First let me say this! Yes the company is out of compliance with the 1.00 share price! But they have until April 15, 2024 to regain or R/S! ONE CAVEAT! They also may be eligible, and will more than likely apply for another 180 extension of the compliance period? With that out of the way!                                                The formal review process of the ONS-5010 MAA by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) is underway with an estimated decision date expected in the first half of 2024. In addition to pursuing potential strategic partnering opportunities in the EU and other regions, Outlook Therapeutics is also exploring potential expanded relationships with Cencora (formerly AmerisourceBergen) to support the launch of ONS-5010 in international markets. If approved, ONS-5010 / LYTENAVA™ (bevacizumab-vikg) would be the first approved ophthalmic formulation of bevacizumab in the U.S. or EU.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
2
1
+0
6
Translate
Report
3746 Views
Comment
Sign in to post a comment
2366Followers
29Following
31KVisitors
Follow